Background: Approximately 15% of ovarian cancer (OC) incidence is attributed to germ-line mutations in BRCA1 or BRCA2 genes. Being a distinct biological subset of OC disease, BRCA1/2-driven cancers are usually characterized by good response to chemotherapy. However, even if OC patient undergoes complete surgical cytoreduction and potentially effective systemic therapy, the probability of the tumor relapse is high. This study aimed to compare some essential clinical features of OC relapses in hereditary vs. sporadic OC. Methods: We identified 212 women with relapsed high-grade serous OC, who were treated in the N.N. Petrov Institute of Oncology within years 2000-2014, underwent complete primary (n ¼ 113) or interval (n ¼ 99) surgical debulking, and had available clinical data for analysis. 66 women were BRCA1/2 germ-line mutation carriers and 146 were mutation negative. Recurrences were classified according to anatomical location (local, regional, distant, marker), type (systemic or discrete) and pattern of spread. Background: Metformin is associated with reduced cancer risk in epidemiological studies and has preclinical anti-cancer activity in ovarian cancer models, likely through inhibition of the mTOR pathway. The primary study objective was to determine the recommended phase II dose (RP2D) of metformin in combination with carboplatin/ paclitaxel in ovarian cancer patients. Secondary objectives were to describe safety and pharmacokinetics. Methods: In this phase Ib single-centre trial the RP2D of metformin in combination with carboplatin/paclitaxel chemotherapy in patients with advanced epithelial ovarian cancer was determined using a 3 þ 3 escalation rule at 3 fixed dose levels: 500 mg tds, 850 mg tds and 1000 mg tds. Chemotherapy consisted of carboplatin AUC6 and paclitaxel 175 mg/m 2 q3w. Metformin was started on day 3 of the first cycle and continued until three weeks after the last chemotherapy administration. The RP2D was defined as the dose level at which 0 of 3 or 1 of 6 evaluable subjects experienced a metforminrelated dose-limiting toxicity (DLT) during chemotherapy cycle 1 or 2. Safety was assessed according to CTCAE v4.0. Pharmacokinetic samples were collected during treatment cycles 1 and 2. Results: Fifteen patients undergoing neo-adjuvant (n ¼ 5) or palliative (n ¼ 10) treatment were included. No DLTs were observed. Three patients discontinued study treatment during cycle 1 for other reasons than DLT. Six patients were treated at the RP2D of metformin 1000 mg tds. Preliminary safety data showed that most common lowgrade toxicities were anemia and hypomagnesaemia. Grade 3 AE's occurred in ten patients, most commonly leukopenia (n ¼ 4), thrombocytopenia (n ¼ 3) and increased GGT (n ¼ 3). There were no grade 4 AE's. Pharmacokinetic analysis showed a metformin induced increase in AUC of carboplatin (D24%, p ¼ 0.028). All metformin trough levels were <4 mg/L. Conclusions: The RP2D of metformin in combination with carboplatin and paclitaxel in advanced ovarian cancer is 1000mg tds. This is higher than the metformin RP2D in combination with targeted agents. The clinical relevance of the metformin-induced increase in carboplatin AUC remains to be elucidated. Clinical trial identification: NCT02312661.
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Legal entity responsible for the study: University Medical Centre Groningen (UMCG Results: One hundred and one female pts with OC diagnosis consented to PT. Pathogenic variants (PV) were found in 19 pts (18.8%): BRCA2 -8 (42%), BRCA1 -5 (26%), RAD51C -3 (16%), RAD51D -2 (11%), RAD50 -1 (5%). The majority of these OC had been previously classified as high-grade serous (HGS) (n ¼ 13 -68%).We identified 2 pts with low-grade serous carcinoma (LGSC) with pathogenic variants (1 BRCA2; 1 RAD51C). Although median age of diagnosis (MAD) was lower for BRCA2 (55 years) and BRCA1 (58 years) than "non-hereditary" and RAD50/RAD51C/ RAD51D pts (both groups with MAD of 63 years), difference was non significant (p ¼ 0.21). As for FH (defined as: other OC and/or BC < 50 years and/or male BC), only 54% of BRCA1/2 pts and none of RAD50/RAD51C/RAD51D had a positive FH. Eighteen percent of "non-hereditary" OC pts had positive FH. With a median follow up of 5 yrs, 63% of pts harboring PV and 50% of those with no PV relapsed, with 2 pts having central nervous system relapses (1 -RAD51D and 1 -RAD50). All but 7 pts were alive at analysis time, only one with a germline mutation impacting HCR (RAD50 mutation). Conclusions: Family history was not associated with the detection of germline pathogenic variants and should not be a criteria for selection of OC for genetic testing. While the inclusion of other genes in our panel may increase our detection rate, excluding LGSC (not included in some guidelines as candidates for testing) would not detect an undetermined number of pts, since the association between LGSC and HOC is not clarified. Longer follow up may help clarify if there is a genotype/phenotype correlation regarding patterns of relapse in hereditary ovarian cancer. Legal entity responsible for the study: Family Risk Clinic -Instituto Português de Oncologia de Lisboa Francisco Gentil EPE. Background: Fibroblast growth factor receptor (FGFR) signaling has been implicated to play a role in tumorigenesis. Aim of this study was to evaluate rate of FGFR2 amplification and preliminary role in patients (pts) with ovarian cancer (OC). Methods: Material from each patient with advanced OC included 3 paraffin-embedded samples: primary ovarian tumor, primary metastatic lesion, and relapse lesion. Samples were analyzed by fluorescence in situ hybridization (FISH) to identify FGFR2 amplification and level of polysomy. Scoring for amplification and polysomy level was adopted from previous studies for gastric cancer [Su et al. BJC 2014] . The analysis was performed in all three samples regardless of the presence of FGFR2 amplification or heterogeneity in primary tumor. Results: 166 samples from 67 pts with advanced ovarian cancer (OC) stage Ic-IV were analysed. Amplification was detected in 11 of 67 pts (16.4%) and high-level polysomy in 31 of 67 (46.3%). All three tumour samples were analyzed in 43 pts. FGFR2 amplification, high-level polysomy were detected in 9 (20.9%) and 19 (44.2%), respectively. Analysis of survival differences revealed no statistically significant difference between 
